{"id":"an2690-solution-5-0","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL2108251","moleculeType":"Oligosaccharide"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting the KCNMA1 channel, AN2690 Solution is thought to reduce the excitability of neurons and potentially alleviate symptoms of certain neurological disorders. The exact mechanism of action is not fully understood, but it is believed to involve a reduction in the frequency and amplitude of action potentials.","oneSentence":"AN2690 Solution is a small molecule that acts as a selective and potent inhibitor of the sodium-activated potassium channel, KCNMA1.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:09:03.736Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of focal epilepsy"}]},"trialDetails":[{"nctId":"NCT00680095","phase":"PHASE1","title":"Cumulative Irritation Test","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-01-22","conditions":"Onychomycosis","enrollment":37},{"nctId":"NCT00679965","phase":"PHASE2","title":"Study of Different Doses of a Novel Treatment for Onychomycosis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-02-28","conditions":"Distal, Subungual Onychomycosis","enrollment":159},{"nctId":"NCT01278394","phase":"PHASE2","title":"Safety and Efficacy Study of Subjects With Onychomycosis of the Great Toenail","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-03","conditions":"Onychomycosis","enrollment":29},{"nctId":"NCT00679523","phase":"PHASE2","title":"Safety and Efficacy Study of Subjects With Onychomycosis of the Great Toenail","status":"COMPLETED","sponsor":"Pfizer","startDate":"2005-11","conditions":"Onychomycosis","enrollment":60},{"nctId":"NCT00679770","phase":"PHASE2","title":"Study of Different Doses of a Novel Treatment for Onychomycosis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-06-30","conditions":"Distal, Subungual Onychomycosis","enrollment":28}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AN2690 Solution, 5.0%","genericName":"AN2690 Solution, 5.0%","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AN2690 Solution is a small molecule that acts as a selective and potent inhibitor of the sodium-activated potassium channel, KCNMA1. Used for Treatment of focal epilepsy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}